Printed From BioPortfolio.com

US FDA accepts for review Amgen's sBLA for Prolia to treat patients with glucocorticoid─induced osteoporosis

09:53 EDT 11 Oct 2017 | PharmaBiz

Amgen has announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia (denosumab) for the treatment of patients with glucocorticoid─induced osteoporosis (GIOP).

Original Article: US FDA accepts for review Amgen's sBLA for Prolia to treat patients with glucocorticoid─induced osteoporosis

More From BioPortfolio on "US FDA accepts for review Amgen's sBLA for Prolia to treat patients with glucocorticoid─induced osteoporosis"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches